Objective: To determine the glucose-lowering mechanism of action and the effects of a quick-release bromocriptine-QR, a D2-dopamine agonist (Cycloset) on vascular function in patients with type 2 diabetes (T2D). Results: HbA 1c decreased from 8.3 ± 0.3% to 7.7 ± 0.2% (P < 0.05), fasting plasma glucose did not change (143 ± 4 vs 147 ± 5) and mean plasma glucose during MTT decreased from 223 ± 3 to 210 ± 4 mg/dL (P < 0.05) after Cycloset. Basal EGP (2.2 ± 0.2 vs 2.1 ± 0.2 mg/kg min) was unchanged, but there was greater MMT suppression (1.1 ± 0.1 vs 0.7 ± 0.1, P < 0.05). After Cycloset, RaO declined from 2.0 ± 0.1 to 1.7 ± 0.2 mg/kg min and peripheral oral glucose appearance from 53.1 ± 3.2 to 44.4 ± 3.1 g (P < 0.01). There were no changes in plasma insulin or glucagon concentration. Systolic (134 ± 4 vs 126 ± 6), diastolic (78 ± 3 vs 73 ± 4), mean BP (97 ± 5 vs 90 ± 4) and pulse pressure (54 ± 2 vs 51 ± 2 mm Hg) were reduced; RHI increased from 1.4 ± 0.1 to 1.9 ± 0.3 au and AS decreased modestly (19.8 ± 4.1 to 16.2 ± 3.7 au, P = NS).
| INTRODUC TI ON
Cycloset (quick-release bromocriptine) is a sympatholytic D2-dopamine agonist approved for the treatment of type 2 diabetes (T2D). Based on animal and human studies, timed bromocriptine administration within 2 hours of awakening has been shown to increase hypothalamic dopamine levels and inhibit excessive sympathetic tone within the central nervous system (CNS), resulting in blood glucose lowering. [1] [2] [3] There is little to no evidence to suggest that Cycloset augments insulin secretion and whether tissue insulin sensitivity improves remains questionable. Addition of Cycloset to poorly controlled patients with T2D
treated with diet alone, metformin, sulfonylureas or a thiazolidinedione produces a 0.5%-0.7% decrement in HbA1c. 4 Published results suggest that Cycloset acts primarily to reduce elevated postprandial glucose levels, 4 but the mechanism(s) underlying this action have yet to be established. In a double-blind, placebo-controlled study of patients with T2D treated with metformin, Cycloset was shown to reduce the composite cardiovascular (CV) end-point of myocardial infarction, stroke and CV mortality by 55%. 5 The reasons behind this drug's beneficial effect on CV disease also remain unexplained.
As patients with T2D are at high risk for atherosclerotic cardiovascular complications, antidiabetic agents that improve glycaemic control and also reduce CV risk are desirable. Hyperglycaemia is a minor risk factor for coronary artery disease and stroke compared with other more established risk factors such as dyslipidaemia, hypertension, obesity and the insulin resistance (metabolic) syndrome. 6, 7 However, even after the treatment of dyslipidaemia and hypertension, weight loss and improved glycaemic control, patients with T2D still remain at high risk for atherosclerotic cardiovascular complications. 7 Among preatherosclerotic conditions, vascular endothelial dysfunction is a common abnormality. 8, 9 To better understand the glucose-lowering mechanisms and CV protective effects of Cycloset, we investigated glucose kinetics using a dual-isotope technique and simultaneously assessed vascular function and CV risk factors. We chose to study poorly controlled patients with T2D treated with a GLP-1 RA as unpublished data (VeroScience, Tiverton, RI, USA) suggested increase glycaemic efficacy of Cycloset in this group. If these two agents were to act via different mechanisms. 10, 11 Cycloset and liraglutide combination therapy might have an additive or even synergistic effect to reduce postprandial plasma glucose levels in patients with T2D. Further, as liraglutide, similar to Cycloset, has been reported to reduce CV events in high-risk patients with T2D, 12 we sought to determine whether the addition of Cycloset would positively affect vascular parameters that could result in enhanced CV outcomes.
| S TUDY DE S I G N AND ME THODS

| Subjects
Fifteen Hispanic (11 females; 4 males) poorly controlled (HbA1c >7.5%) type 2 diabetic patients treated with a stable dose of liraglutide (1.2-1.8 mg/d; n = 15) plus metformin (n = 12) and low-dose glargine insulin (n = 3) participated in the study. Subjects had mean (±SEM) age = 57 ± 9 years, BMI = 33. 
| Study design
On a separate day, subjects who met the entry criteria had a DEXA (Hologic Dexa Scanner, Bedford, MA, USA) in the morning following a 10-to 12-hour overnight fast. Within 3-5 days, subjects returned to the CRC at 0700 hours following a 10-to 12-hour overnight fast for noninvasive hemodynamic testing and a 5-hour meal tolerance test (MMT) with dual-isotope technique (see below).
Subjects refrained from use of caffeine, tobacco, vitamins or medications that might affect vascular tone for 24 hours prior to the study. Upon arrival at the CRC subjects rested for 15 minutes and a cuff was placed around the dominant arm for the measurement of blood pressure. Next, noninvasive assessment of endothelial function was conducted using the Endo-PAT 2000 device (see below).
After ~180 minutes, subjects received a 5-hour dual-isotope MMT. Subjects rested comfortably in supine position in a quiet room and the entire body was scanned. The acquired images were integrated and analysed by a software ibm computer program (Hologic Inc., Bedford, MA, USA) and the total amount of fat, fat-free mass and total body water were estimated.
| Endo-PAT 2000
It was used to evaluate endothelial vasodilator function. 
| Continuous ambulatory blood pressure monitor
Two-day continuous ambulatory BP monitoring (Spacelabs Healthcare, Inc.) was obtained in all subjects after completion of the double-isotope MMT. The BP monitoring device was placed and removed at the TDI Research Center, where the data were downloaded and recorded for analyses. Systolic and diastolic BP were continuously measured and mean BP was automatically calculated, along with average pulse rate and pulse pressure values.
| Double-isotope mixed meal test
Subjects 
| Calculations
During the fasting postabsorptive state, the rate of EGP equals the rate of glucose uptake by all tissues in the body and is calculated as the tritiated glucose infusion rate (DPM/min) divided by the plasma tritiated glucose specific activity (DPM/mg). Following meal ingestion, non-steady-state conditions prevail and the rates of total (RaT) and oral (RaO) glucose appearance in the systemic circulation are calculated using Steele's equation from the plasma 14 C-glucose and 3 H-glucose specific activities, respectively, as previously described. 13 The difference between RaT and RaO yields the rate of EGP. Subtraction of RaO (calculated over the 
| Statistical analyses
The change in HbA 1c , body weight and composition, fasting and post-MMT plasma glucose and FFA concentrations and rates of endogenous (EGP) and exogenous glucose appearance (RaO) in the peripheral circulation between the baseline study and the study performed 4 months after Cycloset treatment were analysed using a paired t test. Similar comparisons were made for the changes in plasma insulin, C-peptide, glucagon and insulin secretion indices, as well as for all measured vascular parameters using the paired t test.
Post hoc testing was carried out with the Bonferroni correction.
Values are presented as mean ± SEM. A P value <0.05 was considered statistically significant.
| Sample size calculations
Assuming that Cycloset would cause a 20% decrease in the rate of total glucose appearance in the systemic circulation (RaT) with a SD of 15%, we computed that 15 subjects would provide 90% power to detect a significant change at an alpha of 0.05.
| RE SULTS
After 4 months of Cycloset, the HbA 1c declined from 8. F I G U R E 1 Plasma glucose concentration following the ingestion of a mixed meal before and 4 mo after Cycloset therapy. The fasting plasma glucose concentration did not change, whereas the mean post-mixed meal plasma glucose concentration decreased after Cycloset therapy. There was a ~22% decline in the incremental area above the fasting plasma glucose, calculated during the 300 min following the mixed meal administration, after Cycloset therapy. *P < 0.01 Before vs After Cycloset F I G U R E 2 Rate of endogenous glucose production following the ingestion of a mixed meal before and after 4 mo of Cycloset therapy. The basal rate of endogenous glucose production did not change, and the per cent suppression over the 300 min post-mixed meal was comparable before and after Cycloset therapy. However, between 240 and 300 min post-mixed meal, the decrease in endogenous glucose production was slightly greater after Cycloset than before Cycloset. *P < 0.05 Before vs After Cycloset Four months of Cycloset therapy had no effect on the pulse rate (Figures 1-3) . The reduced rate of oral glucose appearance is consistent with previous publications. 15, 16 Assuming that there is no delay in gastrointestinal absorption (not measured in the present study), these observations suggest that F I G U R E 3 Rate of oral glucose appearance (RaO) following the ingestion of a mixed meal before and after 4 mo of Cycloset therapy. The rate of oral glucose appearance (RaO) during the 0-300 min of the mixed meal test was significantly decreased, and the total oral glucose load appearance in peripheral blood declined by nearly 20% after Cycloset therapy. The decrement in peripheral appearance of the oral glucose load was documented between 90 and 210 min during the mixed meal test. *P < 0.01 Before vs After Cycloset F I G U R E 4 Rate of total glucose disappearance (Rd) following the ingestion of a mixed meal before and after 4 mo of Cycloset therapy. Basal and post-mixed meal total glucose disappearance rates over the 300-min period of observation were comparable before and after Cycloset therapy Cycloset increases hepatic glucose uptake. Although dopamine binding predominantly to D3 receptors within the intestine may slow gut motility, activation of central dopamine D2 receptors (as with bromocriptine) acts as a primary regulator to increase gut motility, via activation of vagal and reduction in sympathetic efferent activities to the gut. 17, 18 Further, this effect cannot be explained by changes in plasma insulin, glucagon or free fatty acid concentrations. This is the first demonstration in humans that a drug that dampens central sympathetic activity can augment hepatic glucose uptake and is consistent with studies in animals, which have documented an important role of sympathetic overactivity in the development of impaired glucose homeostasis. 19, 20 In addition, our observation that Cycloset therapy was accompanied by a late post-meal EGP suppression is consistent with a sympatholytic effect, brought about by the use of Cycloset on reducing hepatic glucose production, as shown in animal models. 21, 22 Binding of bromocriptine to D2-dopamine receptors in hypothalamic centres is known to restrain sympathetic nervous system activity and, act as a sympatholytic agent. and oxygenation and to promote clearance of toxic waste products from the ischaemic area (also known as reactive hyperaemia). 25 In patients with diabetes, subnormal postischaemic reactive hyperaemia has been ascribed to reduced availability of nitric oxide. 25, 26 Our data indicate that the majority of patients with abnormal reactive hyperaemia at baseline showed significant improvements following treatment with Cycloset. Whether this represents a direct effect of the drug on the vasculature or an indirect effect mediated by the sympatholytic activity and/or improved glycaemic control (ΔA 1c = 0.6%) associated with Cycloset therapy cannot be determined from this study. These results, however, may explain, in part, the cardiovascular protection that has been reported with this antidiabetic agent. [27] [28] [29] [30] In this study, we did not observe any change in the heart rate following exposure to Cycloset, which is in agreement with earlier reports showing either minimal 29 or no change 30 in heart rate. The fact that heart rate did not increase despite a significant fall in arterial blood pressure, however, may be of clinical importance and is expected to occur with central inhibition of sympathetic tone.
The present study has several limitations and the most notable are: first, the relatively small number of subjects who were studied with the purpose of analysing several variables, while statistical power was calculated based solely on anticipated differences in the rate of systemic glucose appearance. The absence of a control group may be viewed as a shortcoming of the study design, although the main objective of the study was to elucidate the glucose-lowering mechanisms with documentation of changes in glucose kinetics, which makes comparisons with a control group less relevant. Thirdly, 14 of the 15 subjects were Hispanic. Whether our results can be extended to T2D individuals of other ethnic backgrounds needs confirmation.
In summary, addition of Cycloset to poorly controlled type 2 diabetes individuals treated with liraglutide resulted in a significant decrease in HbA 1c , which was explained by a reduction in postprandial hyperglycaemia following meal ingestion. These results suggest that Cycloset therapy increases hepatic glucose uptake following glucose ingestion, and it may even help to suppress endogenous glucose output. The decline in arterial blood pressure and pulse pressure, the improvement in endothelial dysfunction and the tendency for arterial stiffness to decline could provide cardiovascular protection and explain, at least in part, the cardiovascular benefits reported with the use of Cycloset. 
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